Ampersand snags $50M as Flagship focuses therapeutics on desired targets only
The behemoth biotech creator Flagship Pioneering is out with another startup aiming to achieve the crown jewel of drug development: treatments that hit only the desired target and cause no unwanted effects elsewhere.
Ampersand Biomedicines is the Boston incubator’s latest biotech to open its blinds, with Flagship dishing out a $50 million check to bankroll initial work.
Leading the charge at Ampersand is Flagship general partner Avak Kahvejian, who’s also founding CEO of ProFound Therapeutics and has been involved in the early days of multiple other companies formed by the engine that sparked Moderna.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.